Michael Staehler

Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

Robert J. Motzer, Thomas E. Hutson, David Cella et al. · New England Journal of Medicine · 2013 · 1.9K citations · Full text

Medicine, Oncology, Pharmacology +13

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update

Börje Ljungberg, Yasmin Abu‐Ghanem, Karim Bensalah et al. · European Urology · 2019 · 1.5K citations

Medicine, Oncology, Urology +16

Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

Bernard Escudier, Tim Eisen, Walter M. Stadler et al. · Journal of Clinical Oncology · 2009 · 1.1K citations · Full text

Medicine, Oncology, Cancer Pharmacology +8

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

Brian I. Rini, Thomas Powles, Michael B. Atkins et al. · The Lancet · 2019 · 1K citations

Medicine, Oncology, Pharmacology +13

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

Steffen Walter, Toni Weinschenk, Arnulf Stenzl et al. · Nature Medicine · 2012 · 784 citations

Medicine, Immunology, Oncology +17